Taeyoung Lee1, Kyung Eun Yun2, Yoosoo Chang2,3, Seungho Ryu2,3, Dong Il Park1, Kyuyong Choi1, Yoon Suk Jung4. 1. Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, 108, Pyung-Dong, Jongro-Ku, Seoul, 110-746, Korea. 2. Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Korea. 3. Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Korea. 4. Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, 108, Pyung-Dong, Jongro-Ku, Seoul, 110-746, Korea. ys810.jung@samsung.com.
Abstract
BACKGROUND: Fatty liver is the hepatic manifestation of metabolic syndrome (MetS) and is a known risk factor for colorectal neoplasia (CRN). Gallbladder (GB) polyps share many common risk factors with CRN. However, studies evaluating CRN risk according to fatty liver severity and the presence of GB polyps are rare. AIM: To investigate CRN risk according to the fatty liver severity and the presence of GB polyps. METHODS: A retrospective cross-sectional study was performed on 44,220 participants undergoing colonoscopy and abdominal ultrasonography (US) as part of a health-screening program. RESULTS: Of the participants, fatty liver was diagnosed as mild in 27.7 %, moderate in 5.1 %, and severe in 0.4 % and 13.4 % were diagnosed with GB polyps. Mean age of participants was 42.7 years. In adjusted models, risk of overall CRN and non-advanced CRN increased with worsening fatty liver severity (P for trend = 0.007 and 0.020, respectively). Adjusted odd ratios for overall CRN and non-advanced CRN comparing participants with mild, moderate, and severe fatty liver to participants without fatty liver were 1.13 and 1.12 for mild, 1.12 and 1.10 for moderate, and 1.56 and 1.65 for severe. The presence of GB polyps did not correlate with CRN risk after adjusting for confounders. CONCLUSIONS: CRN risk increased with worsening fatty liver severity. However the association between GB polyp and CRN was not significant in the presence of other variables. Considering that many people undergo noninvasive abdominal US as a health screen, our study will contribute to colonoscopy screening strategies in people undergoing abdominal US.
BACKGROUND: Fatty liver is the hepatic manifestation of metabolic syndrome (MetS) and is a known risk factor for colorectal neoplasia (CRN). Gallbladder (GB) polyps share many common risk factors with CRN. However, studies evaluating CRN risk according to fatty liver severity and the presence of GB polyps are rare. AIM: To investigate CRN risk according to the fatty liver severity and the presence of GB polyps. METHODS: A retrospective cross-sectional study was performed on 44,220 participants undergoing colonoscopy and abdominal ultrasonography (US) as part of a health-screening program. RESULTS: Of the participants, fatty liver was diagnosed as mild in 27.7 %, moderate in 5.1 %, and severe in 0.4 % and 13.4 % were diagnosed with GB polyps. Mean age of participants was 42.7 years. In adjusted models, risk of overall CRN and non-advanced CRN increased with worsening fatty liver severity (P for trend = 0.007 and 0.020, respectively). Adjusted odd ratios for overall CRN and non-advanced CRN comparing participants with mild, moderate, and severe fatty liver to participants without fatty liver were 1.13 and 1.12 for mild, 1.12 and 1.10 for moderate, and 1.56 and 1.65 for severe. The presence of GB polyps did not correlate with CRN risk after adjusting for confounders. CONCLUSIONS: CRN risk increased with worsening fatty liver severity. However the association between GB polyp and CRN was not significant in the presence of other variables. Considering that many people undergo noninvasive abdominal US as a health screen, our study will contribute to colonoscopy screening strategies in people undergoing abdominal US.
Authors: Seon Hee Lim; Dong Hee Kim; Min Jung Park; Young Sun Kim; Chung Hyun Kim; Jung Yun Yim; Kyung Ran Cho; Sun Sin Kim; Seung Ho Choi; Nayoung Kim; Sang Heon Cho; Byung-Hee Oh Journal: Gut Liver Date: 2007-12-31 Impact factor: 4.519
Authors: M Graif; M Yanuka; M Baraz; A Blank; M Moshkovitz; A Kessler; T Gilat; J Weiss; E Walach; P Amazeen; C S Irving Journal: Invest Radiol Date: 2000-05 Impact factor: 6.016
Authors: Paul J Limburg; Kristin E Anderson; Trista W Johnson; David R Jacobs; Deann Lazovich; Ching-Ping Hong; Kristin K Nicodemus; Aaron R Folsom Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-01 Impact factor: 4.254
Authors: A Stadlmayr; E Aigner; B Steger; L Scharinger; D Lederer; A Mayr; M Strasser; E Brunner; A Heuberger; F Hohla; J Steinwendner; W Patsch; C Datz Journal: J Intern Med Date: 2011-04-25 Impact factor: 8.989
Authors: Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Steven Woon-Choy Tsang; Tina Fan; Winnie Chiu-Wing Chu; Jean Woo; Anthony Wing-Hung Chan; Paul Cheung-Lung Choi; Angel Mei-Ling Chim; James Yun-Wong Lau; Francis Ka-Leung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan Journal: Gut Date: 2011-02-21 Impact factor: 23.059
Authors: Eun Jung Park; Hong Soo Lee; Sang Hwa Lee; Hye Jin Chun; Sun Young Kim; Yu Kyung Choi; Hee Jeong Ryu; Kyung Won Shim Journal: J Korean Med Sci Date: 2013-06-03 Impact factor: 2.153